Skip to content

Study · Non-randomized trial · n = 9,901 · 2023

3 results

Dulaglutide and Kidney Function-Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis.

Botros FT, Gerstein HC, Malik R, Nicolay C, Hoover A, Turfanda I, Colhoun HM, Shaw JE

Diabetes care1 Aug 2023Cited by 33 (Europe PMC)

PMID37343574 (opens in a new tab)DOI10.2337/dc23-0231 (opens in a new tab)PepBankPUB-37343574
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In REWIND participants, dulaglutide reduced the composite kidney outcome versus placebo, with no evidence of differential effects by baseline UACR or eGFR.

    In plain wordsIn people with diabetes, dulaglutide reduced kidney outcome risk compared with placebo, with no evidence of different effects across kidney subgroups.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseComposite kidney function outcome
    Study

    n = 9,901

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    1.5 mgAs given in this study (human).

    Measurements

    Hazard ratio
    0.75 ratio
    dulaglutide versus placebo

    Source sentences

    Summary
    The post hoc composite kidney function-related outcome occurred less frequently among participants assigned to DU than placebo (hazard ratio [HR] 0.75, 95% CI 0.62-0.92, P = 0.004), with no evidence of a differential DU treatment effect by UACR or eGFR subgroup.
    2 context sentences
    Summary · context
    This exploratory post hoc analysis evaluated kidney function-related outcomes, excluding the new-onset macroalbuminuria component, among the REWIND participants.
    Summary · context
    Intent-to-treat analyses were performed on REWIND participants (n = 4,949 DU, n = 4,952 placebo).
  2. 02HumanNon-randomized trialEfficacy outcome

    In REWIND participants, sustained eGFR decline of ≥40% occurred less often with dulaglutide than placebo.

    In plain wordsIn people with diabetes, sustained kidney filtration decline occurred less often with dulaglutide than placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseSustained eGFR decline of ≥40%
    Study

    n = 9,901

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    1.5 mgAs given in this study (human).

    Measurements

    Hazard ratio
    0.72 ratio
    dulaglutide versus placebo

    Source sentences

    Summary
    A ≥40% sustained eGFR decline occurred less frequently among participants assigned to DU than placebo (HR 0.72, 95% CI 0.58-0.88, P = 0.002).
    2 context sentences
    Summary · context
    This exploratory post hoc analysis evaluated kidney function-related outcomes, excluding the new-onset macroalbuminuria component, among the REWIND participants.
    Summary · context
    Intent-to-treat analyses were performed on REWIND participants (n = 4,949 DU, n = 4,952 placebo).
  3. 03HumanNon-randomized trialEfficacy outcome

    In REWIND participants, annual eGFR decline was smaller with dulaglutide than placebo, with similar results across subgroups.

    In plain wordsIn people with diabetes, kidney filtration declined more slowly with dulaglutide than placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseAnnual eGFR decline
    Study

    n = 9,901

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    1.5 mgAs given in this study (human).

    Measurements

    Annual eGFR slope
    −1.37 mL/min/1.73 m2/year
    dulaglutide
    Annual eGFR slope
    −1.56 mL/min/1.73 m2/year
    placebo

    Source sentences

    Summary
    The mean annual decline in eGFR slope was significantly smaller for participants assigned to DU than placebo (-1.37 vs. -1.56 mL/min/1.73 m2/year, P < 0.001); results were similar for all subgroups.
    2 context sentences
    Summary · context
    This exploratory post hoc analysis evaluated kidney function-related outcomes, excluding the new-onset macroalbuminuria component, among the REWIND participants.
    Summary · context
    Intent-to-treat analyses were performed on REWIND participants (n = 4,949 DU, n = 4,952 placebo).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.